Gyre Therapeutics, Inc. Increase (Decrease) in Inventories
Gyre Therapeutics, Inc. (GYRE) reported Increase (Decrease) in Inventories of $921.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-07
- Gyre Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-06-30 was -$94.00K, a 109.85% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2026-03-31 was $1.01M, a 34.13% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-12-31 was $1.21M, a 923.73% increase year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$72.00K, a 111.32% decline year-over-year.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for fiscal 2025 was $3.63M, a 69.75% increase from fiscal 2024.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for fiscal 2024 was $2.14M.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for fiscal 2023 was -$1.75M, a 298.75% decline from fiscal 2022.
- Gyre Therapeutics, Inc. increase (decrease) in inventories for fiscal 2022 was $879.00K.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $921.00K 10-Q · filed 2026-08-07 | $2.13M derived: sum of 3 quarters · filed 2026-08-07 | $2.06M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-08 | $2.22M derived: sum of 2 quarters · filed 2026-05-08 | $2.15M derived: sum of 3 quarters · filed 2026-05-08 | $3.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $1.14M derived: sum of 2 quarters · filed 2026-03-13 | $2.09M derived: sum of 3 quarters · filed 2026-08-07 | $3.63M 10-K · filed 2026-03-13 |
| 2025-09-30 | -$72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $882.00K derived: sum of 2 quarters · filed 2026-08-07 | $2.42M 10-Q · filed 2025-11-07 | $2.54M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $2.50M 10-Q · filed 2026-08-07 | $2.61M derived: sum of 3 quarters · filed 2026-08-07 | $3.25M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $1.54M 10-Q · filed 2026-05-08 | $1.66M derived: sum of 2 quarters · filed 2026-05-08 | $2.29M derived: sum of 3 quarters · filed 2026-05-08 | $3.01M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $754.00K derived: sum of 2 quarters · filed 2026-03-13 | $1.47M derived: sum of 3 quarters · filed 2026-03-13 | $2.14M 10-K · filed 2026-03-13 |
| 2024-09-30 | $636.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.35M derived: sum of 2 quarters · filed 2025-11-07 | $2.02M 10-Q · filed 2025-11-07 | $1.84M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $719.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.39M 10-Q · filed 2025-08-11 | $1.20M derived: sum of 3 quarters · filed 2025-08-11 | $280.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $666.00K 10-Q · filed 2025-05-09 | $482.00K derived: sum of 2 quarters · filed 2025-05-09 | -$439.00K derived: sum of 3 quarters · filed 2025-05-09 | -$556.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$184.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$1.10M derived: sum of 2 quarters · filed 2025-03-17 | -$1.22M derived: sum of 3 quarters · filed 2025-03-17 | -$1.75M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$921.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.04M derived: sum of 2 quarters · filed 2024-11-13 | -$1.56M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$642.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$525.00K 10-Q · filed 2024-05-13 | |||
| 2022-12-31 | $879.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |